Standardization of business processes through shared use of the core system
First written in FY2018-Q2. 1 of 2 entries say "Restated". Latest entry: FY2018-Q3.
The whole theme swung hardest in 2021: 9 of 51 companies on the "Worse" side.
23 other companies' latest entry also says "Restated".
- FY2018-Q3RestatedAnnual report
「In October 2017, our consolidated subsidiary 株式会社恒和薬品 began participating in the joint use of the system. As a result, the core system jointly used across the Group covered approximately 96% of consolidated revenue from the wholesale business for prescription pharmaceuticals and other products. As part of the group management policy of "Strengthening the business as an integrated group," the Group expects to standardize business processes across the Group and reduce total IT costs.」
The company continued to report on 恒和薬品 joining the shared-use system, the approximately 96% coverage and expected standardization of business processes and reduction of IT costs. - FY2018-Q2First statedAnnual report
「In October of the current year, our consolidated subsidiary 恒和薬品 joined the shared-use system. As a result, the core system shared across the Group covered approximately 96% of consolidated revenue from the wholesale business for ethical pharmaceuticals and other products. As part of the Group management policy of “strengthening the business as one Group,” the company expects to standardize business processes across the Group and reduce total IT costs.」
With 恒和薬品 joining the shared-use system, the scope covered by the shared core system reached approximately 96% of consolidated revenue from the wholesale business for ethical pharmaceuticals and other products. This was the first specific disclosure of measures expected to standardize business processes and reduce IT costs.